VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 17, 2007) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that Brian Kuhn, Bernard Byrd, George Kowalchuk and Reza Bahadori have joined the Board of Directors. They will fill vacancies created by the resignations of C. Richard Piazza, Michael Evans, John Osth and Matthias Kurth. The new directors will serve until such time as the shareholders have the opportunity to vote on a new Board of Directors at the 2008 Annual General Shareholders Meeting. Dr. Hassan Salari, founder of the Company, has been appointed Chairman by the new Board of Directors.
